Korean Circ J.  2019 Nov;49(11):1062-1065. 10.4070/kcj.2019.0260.

Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing

• Jeong YH
• Tantry US
• Gurbel PA

• KMID: 2460532
• DOI: http://doi.org/10.4070/kcj.2019.0260

Abstract

No abstract available.

MeSH Terms

Blood Platelets*
Humans
Phenotype*
Platelet Function Tests*

Figure

• 

  Figure 1 Conceptual therapeutic window of platelet reactivity during irreversible and reversible P2Y12 receptor inhibitors.6)

Reference

1. Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y₁₂ receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019; 12:1521–1537.

2. Jaitner J, Stegherr J, Morath T, et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost. 2011; 105:107–112.

3. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011; 57:2474–2483.

4. Hochholzer W, Ruff CT, Mesa RA, et al. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014; 64:361–368.

5. Yun KH, Cho JY, Rhee SJ, Oh SK. Temporal variability of platelet reactivity in patients treated with clopidogrel or ticagrelor. Korean Circ J. 2019; 49:1052–1061.

6. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120:2577–2585.

7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045–1057.

8. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001–2015.

9. Alexopoulos D, Xanthopoulou I, Mavronasiou E, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes Care. 2013; 36:2211–2216.

10. Huo Y, Jeong YH, Gong Y, et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Sci Bull (Beijing). 2019; 64:166–179.